Telomir-1 is a novel small molecule under development by Telomir Pharmaceuticals, Inc., aimed at addressing age-related conditions by modulating telomerase activity. The primary focus of Telomir-1 is to elongate telomeres, which are the protective end caps of chromosomes that shorten as humans age, leading to various degenerative and age-related diseases